XML 68 R61.htm IDEA: XBRL DOCUMENT v3.25.3
Stockholders' Equity - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
May 29, 2025
May 22, 2025
Nov. 27, 2024
Sep. 30, 2025
Jun. 30, 2025
Sep. 30, 2025
Dec. 31, 2024
Stockholders Equity Disclosure [Line Items]              
Aggregate amounts of restricted capital and statutory reserves       $ 66,400,000   $ 66,400,000 $ 64,300,000
Statutory reserve fund           10.00%  
Cumulative amount of statutory reserve fund           50.00%  
Appropriations to statutory reserve           $ 0 $ 0
Gyre [Member] | Gyre Pharmaceuticals              
Stockholders Equity Disclosure [Line Items]              
Issuance of common stock (in shares)       9,184,910   9,184,910  
Proceeds from the issuance of common stock       $ 1,280,000   $ 1,280,000  
Minority interest ownership indirectly holds       69.70% 65.20% 69.70%  
Percentage of diluted minority interest ownership       30.30% 34.80%    
2024 ATM Program              
Stockholders Equity Disclosure [Line Items]              
Proceeeds from issuance of aggregate gross sales     $ 50,000,000        
Percentage of commission for shares sold     3.00%        
Legal expenses incurred     $ 100,000        
Issuance of common stock (in shares)       0   54,734  
Proceeds from the issuance of common stock           $ 509,000  
Commissions and offering costs           8,600  
May 2025 Underwritten Public Offering              
Stockholders Equity Disclosure [Line Items]              
Proceeds from the issuance of common stock           $ 23,000,000  
Common stock issue and sold   2,222,222       2,555,555  
Public offering price   $ 9          
Underwriters option period   30 days          
Offering closing date   May 27, 2025          
Underwriters' discounts and commissions           $ 1,400,000  
Offering costs           300,000  
Net proceeds from issuance of common stock           $ 21,300,000  
Greenshoe Option              
Stockholders Equity Disclosure [Line Items]              
Common stock issue and sold   333,333          
Issuance of additional shares settled 333,333